Supernus Pharmaceuticals’ (SUPN) “Neutral” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their neutral rating on shares of Supernus Pharmaceuticals (NASDAQ:SUPN) in a research note published on Wednesday morning,Benzinga reports. They currently have a $36.00 target price on the specialty pharmaceutical company’s stock.

Supernus Pharmaceuticals Trading Up 0.9 %

Shares of Supernus Pharmaceuticals stock opened at $32.06 on Wednesday. The company has a 50 day moving average of $37.12 and a 200-day moving average of $35.34. Supernus Pharmaceuticals has a 1-year low of $25.53 and a 1-year high of $40.28. The company has a market cap of $1.77 billion, a PE ratio of 29.96 and a beta of 0.90.

Insider Buying and Selling

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. This represents a 10.56 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the transaction, the vice president now owns 10,149 shares of the company’s stock, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,104 shares of company stock worth $440,263 in the last three months. 9.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Several large investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Supernus Pharmaceuticals by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company’s stock worth $222,411,000 after buying an additional 22,852 shares during the period. Stephens Investment Management Group LLC boosted its stake in Supernus Pharmaceuticals by 1.8% during the third quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock worth $60,246,000 after acquiring an additional 33,710 shares in the last quarter. Pacer Advisors Inc. boosted its stake in Supernus Pharmaceuticals by 29.9% during the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock worth $54,655,000 after acquiring an additional 403,028 shares in the last quarter. Geode Capital Management LLC boosted its stake in Supernus Pharmaceuticals by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company’s stock worth $54,633,000 after acquiring an additional 28,517 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in Supernus Pharmaceuticals by 9.2% during the fourth quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company’s stock worth $41,248,000 after acquiring an additional 95,777 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.